Clinical Scientist

Perspective Therapeutics announces acceptance of VMT-α-NET data for oral presentation at the ESMO Congress 2026. GlobeNewswire | Perspective Therapeutics, Inc. Today at 9:22am PDT SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) - Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company's [[212] Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026. | Presenter | Abstract Title | Presentation Details | | Thorvardur Halfdanarson, Mayo Clinic Comprehensive Cancer Center | Cohort level safety and efficacy results for [[212] Pb]VMT-α-NET in advanced somatostatin receptor subtype 2 (SSTR2+)-expressing neuroendocrine tumors (NETs): Cohorts 1-3 | Abstract Number: 2396RO Session Type: Rapid Oral presentation Session Title: Rapid oral: NETs and endocrine tumours Session Date: October 23, 2026 Session Time: 4:15 - 5:45pm CEST / 10:15 - 11:45am EDT Presentation Time: 4:25 - 4:30pm CEST / 10:25 - 10:30am EDT | About [[212]Pb]VMT-α-NET Perspective designed [[212] Pb]VMT-α-NET to target somatostatin receptor subtype 2 (SSTR2), and to deliver the alpha-emitting radioisotope lead-212, or 2[12]Pb, to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation and dose-expansion study (clinicaltrials.gov identifier NCT05636618) of [[212] Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive tumors who have not received prior radiopharmaceutical therapies (RPT). Interim clinical data from the study, with a data cut-off date of April 17, 2026, were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2026. These data included efficacy results for half of the patients in Cohort 2 and both patients in Cohort 1. Initial efficacy data for the remaining patients in Cohort 2 and patients in Cohorts 3 and 4 are pending. The Company plans to submit additional data for presentation at future medical conferences in 2026 and 2027. About Perspective Therapeutics, Inc. Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-generating isotope [212] Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity. The Company is advancing a portfolio of clinical-stage programs in the U.S., including VMT-α-NET (neuroendocrine tumors), VMT01 (melanoma), and PSV359 (solid tumors). The Company is expanding its regional finished drug product candidate supply network, enabled by its proprietary [224] Ra/[212] Pb generator platform used to manufacture clinical drug product candidates, to support the delivery of patient-ready drug product candidates for clinical trials and, if approved, commercial operations. Safe Harbor Statement This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential," or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company's preclinical and clinical development plans and the expected timing for the release of additional data from its clinical programs; the Company's beliefs that its product candidates address certain unmet medical needs; the Company's expectations regarding regulatory pathways for its product candidates; the Company's expectations regarding its interactions with regulatory agencies and the expected timing thereof; the Company's regional distribution and manufacturing capabilities; and other statements that are not historical fact. The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Known risk factors include that the Company's clinical trials may be more costly or take longer to complete than anticipated, or may never be completed, or may not generate results that warrant future development of the tested product candidate; the Company may elect to change its strategy regarding its product candidates and clinical development activities; economic and market conditions may worsen; and risks related to the sufficiency of the Company's cash resources for its future operating expenses and capital expenditures. A more complete discussion of the risks and uncertainties facing the Company appears under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, Newberggraphic undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Media and Investor Relations Contacts: This is a paid placement. For further inquiries, please contact GlobeNewswire directly.

Perspective Therapeutics has appointed Paul Lyne as chief science officer. Co-founder Michael K. Schultz has transitioned to senior scientific advisor as part of a planned move towards retirement. Lyne brings over 25 years of pharmaceutical and biotechnology experience. He most recently served as senior vice president and head of oncology research at Merck KGaA, where he led global research spanning cancer cell signalling, immuno-oncology, and antibody-drug conjugates. Throughout his career, Lyne has advanced more than 30 oncology programmes into clinical development. Perspective Therapeutics is a radiopharmaceutical development company pioneering treatments for cancers. The company uses the alpha-generating isotope 212Pb to deliver radiation to cancer cells via specialised targeting moieties. It is advancing clinical-stage programmes in the US, including VMT-α-NET, VMT01, and PSV359.

Perspective Therapeutics announces acceptance of vmt-α-net data for presentation at the AACR Annual Meeting 2026. Perspective Therapeutics, Inc. - GlobeNewswire - Tue Mar 17, 3:45PM CDT SEATTLE, March 17, 2026 (GLOBE NEWSWIRE) - Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company's [[212] Pb]VMT-α-NET program have been accepted as a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026 taking place from April 17 to 22, 2026 in San Diego, CA as detailed below. AACR has announced that it will release further details for clinical trial abstracts for the conference on April 17, 2026. | Presenter | Abstract Title | Presentation Details | | Thorvardur Halfdanarson, Mayo Clinic Comprehensive Cancer Center | [[212] Pb]VMT-a-NET in advanced SSTR2+ neuroendocrine tumors: safety and preliminary efficacy results from dose-finding cohorts 1, 2 and 3 | Abstract Number: CT088 Session Type: Poster presentation Session Title: Phase I Clinical Trials in Progress Session Date: April 20, 2026 Session Time: 9:00 am - 12:00 pm | About [[212] Pb]VMT-α-NET Perspective designed [[212] Pb]VMT-α-NET to target and deliver [212] Pb to tumor sites expressing somatostatin receptor type 2 (SSTR2). The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study (clinicaltrials.gov identifier NCT05636618) of [[212] Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received prior radiopharmaceutical therapies (RPT). Interim analysis with a data cut-off date of December 10, 2025 was previously reported at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO-GI) in January 2026, including efficacy data on half of the patients in Cohort 2 and both patients in Cohort 1. Initial efficacy data for the remaining patients in Cohort 2 and eight patients in Cohort 3 are pending, and submissions for presentations at additional medical conferences during 2026 are planned. Highlights from the previously presented ASCO-GI analysis included the following: Safety findings based on 56 patients who received at least one treatment: * The 56 patients in this safety analysis comprised 2 patients in Cohort 1 (2.5 mCi), 46 patients in Cohort 2 (5.0 mCi), and 8 patients in Cohort 3 (6.0 mCi). * There were no reports of dose limiting toxicities (DLTs), treatment-related discontinuations, serious renal complications, dysphagia, or clinically significant treatment-related myelosuppression. * Grade 3 or higher treatment-emergent adverse events were reported in 21 patients (37.5%). One of these patients, who was enrolled in Cohort 3, experienced a transient Grade 4 event (lymphocyte count decrease). This event was transient and resolved without medical intervention. The patient continues to receive [[212] Pb]VMT-α-NET treatment. There were no Grade 5 events. * Serious adverse events were reported in 5 patients, with none deemed related to the study medication. Anti-tumor activity based on both patients in Cohort 1 and 23 (half) of the patients enrolled in Cohort 2: * Updated efficacy analysis in the same 25 patients from ESMO Congress 2025 (ESMO 2025) in October 2025 was presented with an additional ~13 weeks of follow-up since the previous presentation at ESMO 2025. * 19 of the 25 patients (76%) were without progression and remained alive, including both patients in Cohort 1. * Nine (39%) patients in Cohort 2 were observed to have response according to investigator-assessed RECIST v1.1. Eight (35%) of those responses were confirmed and previously reported at ESMO 2025. One additional patient experienced an initial response in their most recent tumor assessment after the prior update at ESMO 2025. As the patient remains on study, the patient is expected to receive a subsequent tumor assessment. * Seven patients were observed to have deepening of best response, including one patient with stable disease. About Perspective Therapeutics, Inc. Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope [212] Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary [212] Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations. Safe Harbor Statement This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential," or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company's clinical development plans and the expected timing for the release of additional data from its clinical programs; the Company's expectations regarding its interactions with regulatory agencies and the expected timing thereof; and other statements that are not historical fact. The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Known risk factors include that the Company's clinical trials may be more costly or take longer to complete than anticipated, or may never be completed, or may not generate results that warrant future development of the tested product candidate; the Company may elect to change its strategy regarding its product candidates and clinical development activities; economic and market conditions may worsen; and risks related to the sufficiency of the Company's cash resources for its future operating expenses and capital expenditures. A more complete discussion of the risks and uncertainties facing the Company appears under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Media and Investor Relations Contact: This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.